IXHL icon

Incannex Healthcare

0.6568 USD
-0.2232
25.36%
Updated Jul 31, 11:22 AM EDT
1 day
-25.36%
5 days
-33.23%
1 month
204.50%
3 months
344.38%
6 months
-60.67%
Year to date
-67.49%
1 year
-65.61%
5 years
-98.90%
10 years
-98.90%
 

About: Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.

Employees: 9

0
Funds holding %
of 7,324 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

0.09% less ownership

Funds ownership: 1.91% [Q4 2024] → 1.82% (-0.09%) [Q1 2025]

14% less funds holding

Funds holding: 7 [Q4 2024] → 6 (-1) [Q1 2025]

50% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 2

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

53% less capital invested

Capital invested by funds: $714K [Q4 2024] → $339K (-$375K) [Q1 2025]

Research analyst outlook

We haven’t received any recent analyst ratings for IXHL.

Financial journalist opinion

Based on 4 articles about IXHL published over the past 30 days

Neutral
GlobeNewsWire
3 hours ago
Incannex Confirms Strong Cash Position; No Plans or Requirement to Fully Utilise ATM in Near Term
MELBOURNE, Australia, July 31, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”) announced, in response to recent questions it received from a number of its stockholders, that it does not presently intend to use the full capacity available under its at the market offering program (the “ATM”) in the near-term. As previously disclosed in the Company's Form 8-K filed with the U.S. Securities and Exchange Commission on July 24, 2025, the Company is under no obligation to issue any shares of its common stock pursuant to the ATM and any utilisation of the ATM will be at the discretion of the Company, taking into account prevailing market conditions and strategic priorities.
Incannex Confirms Strong Cash Position; No Plans or Requirement to Fully Utilise ATM in Near Term
Positive
Benzinga
1 day ago
Nano-Cap Incannex's Sleep Apnea Candidate Shows Effectiveness And Safety In Mid-Stage Trial
On Wednesday, Incannex Healthcare Inc. IXHL released topline results from its RePOSA Phase 2 clinical trial evaluating IHL-42X, a novel oral drug candidate for obstructive sleep apnea (OSA), a condition affecting over 900 million people worldwide.
Nano-Cap Incannex's Sleep Apnea Candidate Shows Effectiveness And Safety In Mid-Stage Trial
Neutral
GlobeNewsWire
1 day ago
Incannex Reports Positive Topline Results from RePOSA Phase 2 Trial of IHL-42X
Statistically and clinically significant improvements across key clinical endpoints; IHL-42X reduced AHI by up to 83% from baseline. IHL-42X demonstrates compelling clinical benefit and an outstanding safety profile that exceeded expectations.
Incannex Reports Positive Topline Results from RePOSA Phase 2 Trial of IHL-42X
Neutral
GlobeNewsWire
6 days ago
Incannex Healthcare Expands Clinical Advisory Board to Support Obstructive Sleep Apnea Program with Appointment of Dr. Charlene E. Gamaldo
NEW YORK and MELBOURNE, Australia, July 25, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage biopharmaceutical company advancing combination drug therapies for high-impact indications, announces the appointment of Charlene E. Gamaldo, M.D. to its IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board.
Incannex Healthcare Expands Clinical Advisory Board to Support Obstructive Sleep Apnea Program with Appointment of Dr. Charlene E. Gamaldo
Neutral
GlobeNewsWire
1 month ago
Incannex Healthcare Expands Clinical Advisory Board to Support Obstructive Sleep Apnea Program with Appointment of Dr. Douglas B. Kirsch
NEW YORK and MELBOURNE, Australia, June 24, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage biopharmaceutical company advancing combination drug therapies for high-impact indications, announces the appointment of Douglas B. Kirsch, M.D., FAAN, FAASM to its IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board.
Incannex Healthcare Expands Clinical Advisory Board to Support Obstructive Sleep Apnea Program with Appointment of Dr. Douglas B. Kirsch
Neutral
GlobeNewsWire
1 month ago
Incannex achieves key milestone with database lock for RePOSA Phase 2 trial of IHL-42X
NEW YORK and MELBOURNE, Australia, June 18, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage biopharmaceutical company advancing combination drug therapies for high-impact indications, is pleased to announce that it has achieved database lock for the RePOSA Phase 2 clinical trial of IHL-42X, its lead drug candidate for obstructive sleep apnoea (OSA), on schedule as of 16 June 2025. This marks a major milestone in the development of IHL-42X, confirming the completion of clinical data collection and enabling final statistical analysis to begin.
Incannex achieves key milestone with database lock for RePOSA Phase 2 trial of IHL-42X
Neutral
GlobeNewsWire
1 month ago
Incannex Healthcare Forms Joint Venture with Mind Medicine Australia to Expand Access to Psychedelic-Assisted Therapy
Expanded platform improves access, scales operations, and advances Incannex's position in next-generation mental health treatment Expanded platform improves access, scales operations, and advances Incannex's position in next-generation mental health treatment
Incannex Healthcare Forms Joint Venture with Mind Medicine Australia to Expand Access to Psychedelic-Assisted Therapy
Neutral
GlobeNewsWire
1 month ago
Incannex Healthcare Cancels All Outstanding Series A Warrants Following Strategic ATM Execution
Capital structure streamlined and potential dilution from Series A Warrants eliminated ahead of key Phase 2 clinical milestones Capital structure streamlined and potential dilution from Series A Warrants eliminated ahead of key Phase 2 clinical milestones
Incannex Healthcare Cancels All Outstanding Series A Warrants Following Strategic ATM Execution
Neutral
GlobeNewsWire
1 month ago
Incannex Healthcare Inc. Expands IHL-42X Clinical Advisory Board with Appointments of Four Industry and Academic Leaders to Advance Obstructive Sleep Apnea (OSA) Program
NEW YORK and MELBOURNE, Australia, June 03, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage biopharmaceutical company leading the way in developing oral combination medicines, today announced the recent appointment of four distinguished experts to its IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board:
Incannex Healthcare Inc. Expands IHL-42X Clinical Advisory Board with Appointments of Four Industry and Academic Leaders to Advance Obstructive Sleep Apnea (OSA) Program
Neutral
GlobeNewsWire
2 months ago
Incannex Healthcare Inc. Advances IHL-42X RePOSA Trial to Phase 3 Following FDA Protocol Clearance
NEW YORK and MELBOURNE, Australia, May 29, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage pharmaceutical company developing novel combination therapies, today announced that the Phase 3 component of the RePOSA clinical trial will proceed. The U.S. Food and Drug Administration (FDA) previously reviewed and authorized the protocol to proceed under the Company's Investigational New Drug (IND) application.
Incannex Healthcare Inc. Advances IHL-42X RePOSA Trial to Phase 3 Following FDA Protocol Clearance
Charts implemented using Lightweight Charts™